The TPD field targets hundreds of proteins that are known to be associated with human diseases but were previously thought to be undruggable. Seed Therapeutics, a subsidiary of BeyondSpring, has pioneered a strategy dubbed "molecular glue" to activate the protein degradation mechanism that is present in all cells to recognize and degrade the disease-causing protein. The molecular glue specifically focuses on new chemical entities with more drug-like chemical properties.

Lilly is giving Seed Therapeutics $10 million in upfront cash payments to fund research and a $10 million equity investment. Seed Therapeutics will also be eligible to receive up to approximately $780 million in potential preclinical and clinical development, regulatory, and commercial milestones. The firm may also receive tiered royalties on net sales of products that result from the collaboration. The transaction is subject to customary closing conditions, the firms said.

FDA grants Lilly EUA for its COVID-19 mAb
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Eli Lilly's investigational monoclonal antibody (mAb) therapy,...

Eli Lilly to supply U.S. with 300,000 doses of anti-SARS-CoV-2 antibody
Eli Lilly has entered an initial agreement with the U.S. government to supply 300,000 vials of LY-CoV555 (bamlanivimab), the company's investigational...

Lilly to supply COVID-19 therapy to low-income nations
Eli Lilly and the Bill & Melinda Gates Foundation have launched an initiative to supply low- and middle-income countries with COVID-19 therapeutic...

Eli Lilly seeks EUA from FDA for its SARS-CoV-2 mAbs
Eli Lilly submitted an emergency use authorization (EUA) request from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 monoclonal antibodies...

Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.